Your browser is no longer supported. Please, upgrade your browser.
BCRX BioCryst Pharmaceuticals, Inc. weekly Stock Chart
BCRX [NASD]
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.94 Insider Own1.60% Shs Outstand73.73M Perf Week-3.88%
Market Cap438.72M Forward P/E- EPS next Y-0.83 Insider Trans-77.69% Shs Float72.72M Perf Month6.82%
Income-68.80M PEG- EPS next Q-0.22 Inst Own77.90% Short Float11.45% Perf Quarter49.12%
Sales22.00M P/S19.94 EPS this Y12.80% Inst Trans0.04% Short Ratio8.70 Perf Half Y106.60%
Book/sh0.05 P/B119.00 EPS next Y8.80% ROA-69.00% Target Price7.08 Perf Year-14.88%
Cash/sh0.72 P/C8.31 EPS next 5Y19.90% ROE-296.10% 52W Range1.63 - 7.95 Perf YTD-6.00%
Dividend- P/FCF- EPS past 5Y4.90% ROI-50.60% 52W High-24.65% Beta3.71
Dividend %- Quick Ratio1.20 Sales past 5Y-5.00% Gross Margin100.00% 52W Low267.48% ATR0.41
Employees70 Current Ratio1.30 Sales Q/Q-29.10% Oper. Margin- RSI (14)44.93 Volatility5.64% 7.53%
OptionableYes Debt/Eq13.35 EPS Q/Q21.70% Profit Margin- Rel Volume0.58 Prev Close5.95
ShortableYes LT Debt/Eq6.33 EarningsFeb 06 BMO Payout- Avg Volume956.82K Price5.99
Recom2.60 SMA20-7.85% SMA501.54% SMA20041.49% Volume38,447 Change0.67%
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
Feb-09-16Downgrade JP Morgan Overweight → Neutral
Feb-09-16Downgrade Jefferies Buy → Hold
Feb-08-16Downgrade Piper Jaffray Overweight → Neutral
Jan-06-16Upgrade Jefferies Hold → Buy
Nov-11-15Downgrade BofA/Merrill Neutral → Underperform
Oct-09-15Downgrade BofA/Merrill Buy → Neutral
Sep-09-15Initiated Jefferies Hold
Jun-30-15Upgrade BofA/Merrill Neutral → Buy $12 → $19
Apr-21-15Initiated FBR Capital Outperform $18
Apr-20-15Upgrade BofA/Merrill Underperform → Neutral $8 → $12
May-30-14Reiterated H.C. Wainwright Buy $21 → $24
Mar-04-14Reiterated MLV & Co Buy $9 → $15
Feb-28-14Initiated Oppenheimer Perform
Feb-20-14Initiated Mizuho Buy $23
Feb-18-14Initiated Needham Buy $14
Dec-19-13Reiterated MLV & Co Buy $6.50 → $9
Jan-09-17 06:04AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -11.08%
Jan-08-17 03:30PM  BioCryst Receives Health Canada Approval for RAPIVAB® for the Treatment of Influenza GlobeNewswire
Jan-04-17 06:45AM  BioCryst to Present at the J.P. Morgan Healthcare Conference GlobeNewswire +8.18%
Dec-29-16 04:36AM  Can The Uptrend Continue for BioCryst Pharmaceuticals (BCRX)?
Dec-22-16 08:40AM  Are Options Traders Betting on a Big Move in BioCryst (BCRX) Stock?
Dec-19-16 10:45AM  Finally Getting Back to a Stock Picker's Market +10.66%
Dec-16-16 03:14PM  A Trump Presidency May Be Good for Biotech +11.13%
11:46AM  Shark Bites: What, Market Worry?
11:12AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 16, 2016
Dec-05-16 11:50AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 5, 2016
08:48AM  What Smart Money Thinks about BioCryst Pharmaceuticals, Inc. (BCRX)? at Insider Monkey
Nov-23-16 12:42PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : November 23, 2016
Nov-22-16 10:42AM  BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
Nov-17-16 07:05AM  BioCryst to Present at the Piper Jaffray Healthcare Conference November 30 GlobeNewswire
Nov-16-16 01:04PM  BIOCRYST PHARMACEUTICALS INC Financials
Nov-10-16 07:14AM  How investors are playing Biocryst
Nov-09-16 12:29PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : November 9, 2016 +7.49%
Nov-08-16 02:26PM  BIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
07:52AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : November 8, 2016
Nov-07-16 12:29PM  Edited Transcript of BCRX earnings conference call or presentation 7-Nov-16 4:00pm GMT +14.83%
08:02AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos
07:07AM  Q3 2016 BioCryst Pharmaceuticals Inc Earnings Release - Before Market Open
06:56AM  BioCryst reports 3Q loss
06:48AM  BioCryst Reports Third Quarter 2016 Financial Results GlobeNewswire
Oct-26-16 02:50PM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
02:30PM  BioCryst Announces Late Breaker Presentation of Galidesivir (BCX4430) Nonclinical Results in Zika Virus Infection at IDWeek 2016 GlobeNewswire
Oct-24-16 02:40PM  BioCryst to Announce Third Quarter 2016 Financial Results November 7 GlobeNewswire
Oct-21-16 08:14AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : October 21, 2016
Oct-19-16 11:02AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 19, 2016
Oct-10-16 08:38AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BCRX-US : October 10, 2016
Sep-26-16 07:26AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin
06:47AM  BioCryst Closes $23 Million Senior Credit Facility GlobeNewswire
Sep-22-16 01:10PM  5 Stocks Under $10 That Could Make You a Lot of Money
Sep-21-16 10:18AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : September 21, 2016
Sep-07-16 01:51PM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +12.11%
06:58AM  BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model GlobeNewswire
Aug-31-16 02:40PM  BioCryst to Present at the Baird 2016 Global Healthcare Conference September 8 GlobeNewswire
Aug-29-16 11:04AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : August 29, 2016
Aug-23-16 08:04AM  Biocryst Pharmaceuticals Inc (BCRX): Billionaire David E. Shaws Fund Increases Stake at Insider Monkey
Aug-17-16 10:02AM  Biocryst Pharmaceuticals Inc (BCRX): Baker Bros. Advisors Unloads Nearly 4 Million Shares at Insider Monkey
Aug-15-16 10:13AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : August 15, 2016 -6.35%
Aug-12-16 12:36PM  BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
07:12AM  BioCryst Pharma upgraded by Piper Jaffray
Aug-11-16 12:05PM  Here's the Buzz Behind BioCryst Pharmaceuticals, Inc.'s 27% Gain in July at Motley Fool
10:28AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:18AM  BioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema GlobeNewswire
Aug-10-16 01:24PM  Bulls pile into Biocryst Pharmaceuticals
08:15AM  BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 18.1%
Aug-08-16 03:42PM  BIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Aug-06-16 12:11PM  Watch these biotechs as the Zika virus moves to the U.S. at MarketWatch
Aug-05-16 04:30PM  Edited Transcript of BCRX earnings conference call or presentation 4-Aug-16 3:00pm GMT
Aug-04-16 09:37AM  BioCryst reports 2Q loss
09:27AM  Try these good-times stocks in a market thats going nowhere at MarketWatch
09:12AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos
07:07AM  Q2 2016 BioCryst Pharmaceuticals Inc Earnings Release - Before Market Open
06:55AM  BioCryst Reports Second Quarter 2016 Financial Results GlobeNewswire
Jul-29-16 06:59AM  8 Stocks Under $10 to Trade for Huge Profits
Jul-28-16 08:25AM  BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 13.7%
Jul-21-16 07:15AM  BioCryst to Announce Second Quarter 2016 Financial Results August 4 GlobeNewswire
Jul-07-16 02:45PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : July 7, 2016
Jul-05-16 08:11AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial
07:30AM  BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases GlobeNewswire
May-31-16 12:31PM  Most Popular Healthcare Stocks Under $5 at Insider Monkey
09:15AM  Early Morning Technical Highlights on Biotech Stocks
May-26-16 07:19PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : May 26, 2016
08:55AM  BioCryst to Present at Two Upcoming Investor Conferences GlobeNewswire
May-25-16 11:49AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to
May-24-16 10:53AM  Biotech-Focused VHCP Managements Bullish Moves and New Picks at Insider Monkey
May-12-16 02:55PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : May 12, 2016
May-11-16 11:21AM  BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q1, 2016 By the Numbers
May-09-16 03:04PM  Edited Transcript of BCRX earnings conference call or presentation 5-May-16 3:00pm GMT +7.75%
02:06PM  BIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
May-05-16 10:50AM  BioCryst reports 1Q loss -9.00%
07:15AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos
07:07AM  Q1 2016 BioCryst Pharmaceuticals Inc Earnings Release - Time Not Supplied
06:44AM  BioCryst Reports First Quarter 2016 Financial Results GlobeNewswire
Apr-21-16 06:48AM  BioCryst to Announce First Quarter 2016 Financial Results May 5 GlobeNewswire +7.35%
Apr-15-16 03:10PM  The best-run public companies in the Research Triangle area at bizjournals.com
07:59AM  7 Stocks Under $10 Making Big Moves at TheStreet
Apr-07-16 09:30AM  BioCryst to Present at Two Upcoming Investor Conferences GlobeNewswire
Apr-01-16 07:02AM  These 5 Biotech Stocks Under $10 Are About to Break Out at TheStreet
Mar-29-16 02:48PM  Venrock Healthcare Capital Partners Discloses 7.1% Stake in Biocryst Pharmaceuticals Inc (BCRX) at Insider Monkey
09:35AM  8 Major Biopharma Events Coming Later in 2016 and in 2017 at 24/7 Wall St.
Mar-17-16 11:11AM  Valeant Stock Plunge Puts Focus on Chairman Ingram and His Many Hats at TheStreet +6.15%
Mar-16-16 01:36PM  D. E. Shaw & Co Raises Exposure to Biocryst Pharmaceuticals Inc (BCRX) at Insider Monkey
Mar-09-16 09:43AM  The Biotech Bull Market Is Back Accesswire
09:30AM  BioCryst to Present at Barclays Healthcare Conference GlobeNewswire
Mar-08-16 09:39AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
08:15AM  BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 15.5%
Mar-07-16 02:25PM  Here's Why BioCryst Pharmaceuticals (BCRX) Stock is Spiking Today at TheStreet +15.50%
07:24AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:21AM  BioCryst's Zika drug shows promise in mice
06:45AM  Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference GlobeNewswire
Feb-26-16 04:51PM  BIOCRYST PHARMACEUTICALS INC Files SEC form 10-K, Annual Report +11.62%
01:55PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : February 26, 2016
08:54AM  5 Stocks Poised for Breakouts at TheStreet
Feb-24-16 11:06AM  BioCryst Pharmaceuticals, Inc. Earnings Analysis: 2015 By the Numbers
08:00AM  Healthcare Stocks to Remedy any Portfolio BCRX, ANAC, ALDR, and FGEN Accesswire
Feb-23-16 05:46PM  Edited Transcript of BCRX earnings conference call or presentation 23-Feb-16 4:00pm GMT -12.04%
07:19AM  BioCryst reports 4Q loss
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II/III clinical trial for hereditary angioedema (HAE); BCX7353, an oral serine protease inhibitor, which is in Phase II clinical trial for HAE; and other second generation HAE compounds, an oral serine protease inhibitor, which is in preclinical stage. The company's product candidates also comprise BCX4430, an RNA dependent-RNA polymerase inhibitor that is in Phase I clinical trial for treating Filoviruses, including Ebola and Marburg viruses; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in preparation to file for regulatory approval. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; and Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STAAB THOMAS R IISenior Vice President and CFODec 19Option Exercise3.783,25012,285127,437Dec 21 10:42 AM
STAAB THOMAS R IISenior Vice President and CFODec 19Sale7.453,25024,213124,187Dec 21 10:42 AM
Barnes Alane PVP, General Counsel & Corp SecSep 14Sale4.278,35735,68479,377Sep 16 10:54 AM
Babu Yarlagadda SSenior VP - Drug DiscoveryAug 25Sale4.0630,000121,800111,428Aug 29 10:46 AM
BAKER BROS. ADVISORS LP10% OwnerAug 16Sale4.299904,2461,551,387Aug 16 06:11 PM
BAKER BROS. ADVISORS LP10% OwnerAug 15Sale4.83400,0001,931,0401,551,527Aug 16 06:11 PM
STAAB THOMAS R IISenior Vice President and CFOAug 12Sale5.224,55823,793124,187Aug 15 02:07 PM
BAKER BROS. ADVISORS LP10% OwnerAug 12Sale5.023,645,60018,315,8171,607,944Aug 16 06:11 PM
STAAB THOMAS R IISenior Vice President and CFOAug 11Sale5.051,3066,595128,745Aug 15 02:07 PM
STAAB THOMAS R IISenior Vice President and CFOAug 09Sale4.4314,57764,576130,051Aug 11 01:53 PM
BAKER BROS. ADVISORS LP10% OwnerFeb 05Buy6.3345,000284,65712,894,240Feb 09 05:24 PM
BAKER BROS. ADVISORS LP10% OwnerFeb 04Buy6.6524,800164,91512,849,240Feb 04 05:15 PM
BAKER BROS. ADVISORS LP10% OwnerFeb 03Buy6.2991,187573,31112,824,440Feb 04 05:15 PM
BAKER BROS. ADVISORS LP10% OwnerFeb 02Buy6.5291,728598,36012,733,253Feb 04 05:15 PM
Barnes Alane PVP, General Counsel & Corp SecJan 29Option Exercise1.4219,36827,50385,057Feb 01 02:34 PM
BAKER BROS. ADVISORS LP10% OwnerJan 28Buy6.8825,000172,01512,641,525Jan 29 04:42 PM
BAKER BROS. ADVISORS LP10% OwnerJan 27Buy6.9863,345441,97112,616,525Jan 29 04:42 PM
Stonehouse Jon PPresident & CEOJan 20Option Exercise4.1524,09699,998676,326Jan 21 01:12 PM
BAKER BROS. ADVISORS LP10% OwnerJan 20Buy6.8752,695362,17112,446,380Jan 20 07:13 PM